Expanding Product Portfolio Orphalan's recent acquisition of Orphelia Pharma enhances its expertise and product offerings in pediatric neurology and oncology, presenting opportunities to cross-sell and expand market reach for specialized rare disease treatments.

International Market Entry The US launch of Cuvrior and strategic partnerships in developing countries demonstrate Orphalan’s focus on global expansion, opening avenues to target healthcare providers and government agencies involved in rare disease management worldwide.

Focus on Rare Diseases As a dedicated orphan drug developer with a clear emphasis on rare and serious conditions, Orphalan offers tailored solutions to specialized clinics and centers, creating opportunities for collaborative sales and targeted outreach.

Innovative Treatment Offerings With patented products like Cuvrior addressing Wilson’s disease, Orphalan can leverage its innovative portfolio to approach hospitals and specialists seeking advanced therapies for niche patient populations.

Strong Industry Presence The company's active partnership initiatives and recent product launches position Orphalan as a trusted player in the orphan drug market, making it a compelling partner for healthcare organizations looking to expand their rare disease treatment options.